Last updated 2026-11-03
- Raised $1.6B debt round led by Teva Finance II, Sep 2026
- Raised $4.9B debt round led by Teva Pharmaceutical Finance Netherlands II B.V., Sep 2026
- Raised $900M grant led by Direct Relief, Apr 2026
Total raised
$76.7B
Last: Debt Financing 2026-03
Stage
Public
Founded
1901
Headcount
36,830
HQ
Tel Aviv, Israel
Sector
Health Tech & Life Sciences
About
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company specializing primarily in generic drugs, but also in branded-drugs, active pharmaceutical ingredients (APIs), and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva focuses on innovative medicine for various therapeutic areas including neuroscience and immunology for non- and rare diseases. The company's portfolio covers a wide range of therapeutic areas, including central nervous system disorders, respiratory conditions, oncology, and more. Teva aims to help patients live longer, healthier lives and is dedicated to addressing patients' needs, now and in the future.
Funding history · 31 rounds · $76.7B total
31 events/rounds · $76.7B Total Funding: $8.2B in Private Equity, $14.3B in Public Equity, $53.3B in Debt
Sep 2026
★ Teva Finance II★ Teva Finance IV★ Teva Finance III
Sep 2026
★ Teva Pharmaceutical Finance Netherlands II B.V.★ Teva Pharmaceutical Finance Netherlands IV B.V.★ Teva Pharmaceutical Finance Netherlands III B.V.
Apr 2026
Grant
$900.0M
prior (startupim db)
★ Direct Relief★ National Association of Free and Charitable Clinics (NAFC)
Mar 2026
Public Offering
$400.0M
prior (startupim db)
Jan 2026
Jan 2026
Public Offering
$2.3B
prior (startupim db)
Nov 2025
★ Startup Nation Central★ Israel Innovation Authority
May 2025
★ HSBC★ Public★ BNP PARIBAS★ J.P. Morgan★ Public investors★ Teva Pharmaceutical Finance Netherlands II B.V.★ Teva Pharmaceutical Finance Netherlands IV B.V.★ Teva Pharmaceutical Finance Netherlands III B.V.MUFGMizuhoCitigroupHSBC Bank plcBofA SecuritiesIMI-Intesa SanpaoloIntesa Sanpaolo S.p.A.PNC Capital Markets LLCJ.P. Morgan Securities plcMerrill Lynch InternationalGoldman Sachs Bank Europe SE
Mar 2024
PIPE
$150.0M
prior (startupim db)
Jan 2024
Public Offering
$10.0B
prior (startupim db)
★ Public
Nov 2023
★ Royalty Pharma
Mar 2023
Debt Financing
$864.0M
prior (startupim db)
★ Public★ Public investors★ Teva Pharmaceutical Finance Netherlands II B.V.★ Teva Pharmaceutical Finance Netherlands III B.V.
Mar 2023
Debt Financing
$500.0M
prior (startupim db)
Nov 2021
Debt Financing
$1.0B
prior (startupim db)
Nov 2021
Public Offering
$1.6B
prior (startupim db)
★ Public★ Public investors★ Teva Pharmaceutical Finance Netherlands II B.V.★ Teva Pharmaceutical Finance Netherlands III B.V.
Jan 2018
PIPE
$1.3B
prior (startupim db)
★ Public★ JANA Partners★ Public investors★ Fidelity Ventures★ Berkshire Hathaway★ Fidelity Investments★ Teva Pharmaceutical Finance Netherlands III B.V.
Jul 2016
Debt Financing
$3.5B
prior (startupim db)
Jul 2016
Debt Financing
$2.0B
prior (startupim db)
Jul 2015
★ Citi★ BNP Paribas★ Mizuho Bank★ Credit Suisse★ Barclays Bank PLC★ Bank of America Merrill Lynch★ HSBC Ventures★ Morgan Stanley Senior Funding, Inc.HSBCRBC Capital MarketsMorgan Stanley Senior FundingSumitomo Mitsui Banking Corporation
Apr 2012
Debt Financing
$1.1B
prior (startupim db)
Mar 2012
May 2011
D Round
$6.8B
prior (startupim db)
Sep 2007
Feb 2006
Debt Financing
$1.0B
prior (startupim db)
Feb 2006
Debt Financing
$500.0M
prior (startupim db)
Feb 2005
A Round
Undisclosed
prior (startupim db)
Feb 1987
Public Offering
Undisclosed
prior (startupim db)
★ NASDAQPublic
1982
Public Offering
Undisclosed
prior (startupim db)
Dec 1981
Public Offering
Undisclosed
prior (startupim db)
Jan 1951
Public Offering
Undisclosed
prior (startupim db)
May 1935
Seed
Undisclosed
prior (startupim db)
★ Else Kober★ Günther Friedländer★ loans from German immigrants★ Günther Friedländer family capitalFamily capitalAlfred FeuchtwangerFamily's own capitalloans from other German immigrants
Acquisitions · 27
Oct 2026
BioXcel Therapeutics (neuroscience assets)
$57.5M
Jun 2026
Emalex Biosciences
$700.0M
Oct 2016
Anda
$500.0M
Aug 2016
Actavis Generics
$40.0B
Oct 2015
Rimsa
$2.3B
Oct 2015
Gecko Health Innovations
Undisclosed
Mar 2015
Auspex Pharmaceuticals
$3.5B
Jun 2014
Labrys Biologics
$825.0M
Jan 2014
NuPathe
$144.0M
Jun 2013
MicroDose Therapeutx
$165.0M
Jul 2011
Taiyo Pharmaceutical Industry
$934.0M
May 2011
Cephalon
$6.8B
Mar 2010
Ratiopharm
$5.0B
Dec 2008
Barr Pharmaceuticals
$7.5B
Jul 2008
Bentley Pharmaceuticals (generic operations)
$360.0M
Jan 2006
Ivax Corporation
$7.4B
Jan 2004
Sicor, Inc.
Undisclosed
Jan 2000
Novopharm
Undisclosed
Aug 1999
Copley Pharmaceutical
$220.0M
Jan 1996
Biocraft
Undisclosed
Jan 1995
Biogal Gyógyszergyár Rt.
Undisclosed
Jan 1995
ICI (Italy)
Undisclosed
Jan 1985
Lemmon Pharmacal Company
Undisclosed
Jan 1980
Ikapharm
Undisclosed
Jan 1980
Plantex
Undisclosed
Jan 1976
Assia and Zori
Undisclosed
Date unknown
Orphahell
Undisclosed
Offices
Tel Aviv, Israel · HQ / main office
Q&A
- What is Teva Pharmaceuticals' primary focus?
- Teva Pharmaceuticals is an Israeli multinational pharmaceutical company specializing primarily in generic drugs, but also in branded-drugs, active pharmaceutical ingredients (APIs), and contract manufacturing services.
- When was Teva Pharmaceuticals founded and where is its headquarters?
- Teva Pharmaceuticals was founded in 1901 and is headquartered in Tel Aviv, Israel.
- How many employees does Teva Pharmaceuticals have?
- Teva Pharmaceuticals has over 500 employees.
- What was Teva Pharmaceuticals' most recent debt financing round?
- In September 2026, Teva Pharmaceuticals secured a Debt Financing round worth $4.9 billion from Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Finance Netherlands IV B.V., and Teva Pharmaceutical Finance Netherlands III B.V.
- What was Teva Pharmaceuticals' most recent Public Offering?
- In March 2026, Teva Pharmaceuticals had a Public Offering of $400 million, with investors including Blackstone.
- What was Teva Pharmaceuticals' most recent acquisition?
- In October 2026, Teva Pharmaceuticals acquired the neuroscience assets of BioXcel Therapeutics for $57.5 million.
- Which company did Teva Pharmaceuticals acquire in June 2026?
- In June 2026, Teva Pharmaceuticals acquired Emalex Biosciences for $700 million.
- What was the amount of the PIPE round Teva Pharmaceuticals received in March 2024?
- In March 2024, Teva Pharmaceuticals received a PIPE round of $150 million from Abingworth.
Team · 23
Chaim Salomon
Founder · founders
Moshe Levin
Founder · founders
Yitschak Elstein
Founder · founders
Günther Friedländer
Founder · founders
Richard Francis
President and CEO
Eli Kalif
Executive Vice President, Chief Financial Officer (CFO)
Dr. Eric A. Hughes
Executive Vice President, Global R&D and Chief Medical Officer
Richard Daniell
Executive Vice President, European Commercial
Christine Fox
Executive Vice President, US Commercial, Head of Innovative Franchise
Placid Jover
Executive Vice President, Chief Human Resources Officer
Evan Lippman
Executive Vice President, Business Development
Mark Sabag
Executive Vice President, International Markets Commercial
Matthew Shields
Executive Vice President, Teva Global Operations
Nir Baron
Senior Vice President, Chief Internal Auditor
Kathleen Veit
Senior Vice President, Global Compliance & Ethics Officer
Sol Barer
Chairman
Rosemary A. Crane
board
Amir Elstein
board
Chen Lichtenstein
board
Gerald M. Lieberman
board
Roberto A. Mignone
board
Dr. Perry D. Nisen
board
Prof. Ronit Satchi-Fainaro
board
Sectors & technology
Primary sector
Health Tech & Life Sciences
Target customers
Business model
B2BB2C
Highlights
Patents
Tags
respiratorywomen-healthneurologyoncologygeneric-drugsbiological-therapypharmaceuticalspatientsbiopharmaceuticalnanotechnologychronic-patientsdrug-deliverydoctorsmedical-cannabis
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | tevapharm.com |
|---|---|
| linkedin.com/company/5239 | |
| X / Twitter | twitter.com/tevapharm |
| facebook.com/tevapharm | |
| YouTube | youtube.com/channel/UC9mY1-jUvXsEIS5A2_EjpFg |
| Wikipedia | en.wikipedia.org/wiki/Teva_Pharmaceuticals |
| Wikidata | wikidata.org/wiki/Q898750 |
Identifiers & details
| Legal name | Teva Pharmaceutical Industries Ltd. |
|---|---|
| Founded | 1901 |
| Employees (exact) | 36830 |
| Wikidata QID | Q898750 |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| BioXcel Therapeutics (neuroscience assets) | 2026-10 | $57.5M |
| Emalex Biosciences | 2026-06 | $700.0M |
| Anda | 2016-10 | $500.0M |
| Actavis Generics | 2016-08 | $40.0B |
| Rimsa | 2015-10 | $2.3B |
| Gecko Health Innovations | 2015-10 | |
| Auspex Pharmaceuticals | 2015-03 | $3.5B |
| Labrys Biologics | 2014-06 | $825.0M |
| NuPathe | 2014-01 | $144.0M |
| MicroDose Therapeutx | 2013-06 | $165.0M |
| Taiyo Pharmaceutical Industry | 2011-07 | $934.0M |
| Cephalon | 2011-05 | $6.8B |
| Ratiopharm | 2010-03 | $5.0B |
| Barr Pharmaceuticals | 2008-12 | $7.5B |
| Bentley Pharmaceuticals (generic operations) | 2008-07 | $360.0M |
| Ivax Corporation | 2006-01 | $7.4B |
| Sicor, Inc. | 2004-01 | |
| Novopharm | 2000-01 | |
| Copley Pharmaceutical | 1999-08 | $220.0M |
| Biocraft | 1996-01 | |
| Biogal Gyógyszergyár Rt. | 1995-01 | |
| ICI (Italy) | 1995-01 | |
| Lemmon Pharmacal Company | 1985-01 | |
| Ikapharm | 1980-01 | |
| Plantex | 1980-01 | |
| Assia and Zori | 1976-01 | |
| Orphahell |
Radar intelligence
Patents
| EPO | 1106 |
|---|
App Store
| App | Rating | Ratings |
|---|---|---|
| Teva Pharmaceutical Events | ||
| Teva Meetings |
Web history (Wayback)
| Domain | tevapharm.com |
|---|
Wikidata
| QID | Q898750 |
|---|
Certificate / subdomain footprint
| Subdomains | 200 |
|---|